PMC:7443692 / 10640-10785 JSONTXT

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T42","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T43","span":{"begin":77,"end":90},"obj":"Chemical"}],"attributes":[{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_28300"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_133469"}],"text":"2 begin with an N-terminal glutamine that has undergone condensation to form pyroglutamine at residues 14 and 18, respectively (Figures 1D and S1"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T50","span":{"begin":27,"end":36},"obj":"Body_part"}],"attributes":[{"id":"A50","pred":"fma_id","subj":"T50","obj":"http://purl.org/sig/ont/fma/fma82752"}],"text":"2 begin with an N-terminal glutamine that has undergone condensation to form pyroglutamine at residues 14 and 18, respectively (Figures 1D and S1"}